Abstract. Previous research has revealed that the von-Hippel-Lindau tumor suppressor protein (pVHL) may downregulate never-in-mitosis A-related kinase 8 (NEK8) via hypoxia-inducible factor-α (HIF-α). The HIF-independent functions of pVHL also serve an important role in its tumor-suppressor action. In the present study, the association between pVHL and NEK8 was demonstrated in the human gastric cancer cell line, SGC-7901, indicating a direct interaction of pVHL with NEK8. Subsequently, it was reported that MG-132, a specific proteasome inhibitor, may attenuate pVHL overexpression-induced reductions in NEK8 protein expression levels. In addition, the present study revealed that pVHL may stimulate the rapid degradation of NEK8 protein and promote its ubiquitination. The association between the expression profile of NEK8 and the survival status of patients with gastric cancer was analyzed from an online database. Kaplan-Meier survival plots indicated that higher expression levels of NEK8 may lead to poor survival, as suggested by the transcriptomic data of 1,065 patients with gastric cancer. It was found that NEK8-knockdown mediated by RNA interference inhibited SGC-7901 and SNU-1 proliferation, colony formation and migration in vitro, and tumor growth in vivo. Collectively, the present study proposed that NEK8 may be a novel target of pVHL as a ubiquitin E3 ligase, and may serve a role as a potential oncoprotein in human gastric cancer.

Introduction

Gastric cancer (GC) is the fourth most common cause of cancer-associated mortality worldwide, as the majority of patients initially present at an advanced stage of the disease; the prognosis is poor with a 6-month survival rate of <15% (1). Since GC is a heterogeneous disease with various genetic mutations, in addition to current histological classification systems, including Lauren (2) and the World Health Organization (3) systems, it has been of great focus to determine a novel molecular classification system in the age of high-throughput technology. As reviewed by Cisło et al (4), The Cancer Genome Atlas (TCGA) sought to identify the subtypes of GC using complex statistical analyses of molecular data that had been obtained from six molecular analysis platforms that included DNA sequencing, RNA sequencing and protein arrays. A total of four major genomic subtypes of GC were proposed, including Epstein Barr Virus-positive, microsatellite instability, genomically stable and chromosomal instability.

In the present study, never-in-mitosis A-related kinase 8 (NEK8) gene expression data and relapse-free and overall survival information were further analyzed from Gene Expression Omnibus (GEO; https://www.ncbi.nlm.nih.gov/geo; Affymetrix microarrays only; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and the European Genome-Phenome Archive (EGA; https://www.ebi.ac.uk/ega/home), in addition to TCGA, using online tool (http://kmplot.com/analysis/) (5). It was revealed that higher expression levels of NEK8 lead to poor survival outcomes associated with GC, indicating that NEK8 may be associated with the development of GC.

NEK8 is a member of the serine/threonine protein kinase family associated with never in mitosis, gene A (NIMA) of Aspergillus nidulans (6-8), and it has been reported to serve a role in the progression of the cell cycle from the G2 to M phase (9), primary cilia disassembly (10,11) and activation of the DNA damage response signaling pathway (9,12). Holland et al (13) identified NEK8 as a novel
NIMA-associated kinase and also its candidate target BICD cargo adaptor, which has been associated with microtubule dynamics, independent of the cell cycle. In addition, it has been reported in several studies that NEK8 regulates ciliary stability via polycystin-1, polycystin-2 (11), yes-associated protein (14), galectin-1, sorcin and vimentin proteins (15). It has previously been reported that NEK8 may serve a potential role in tumorigenesis and the DNA damage response via MYC proto-oncogene, BHLH transcription factor (16), RAD51 recombinase (17) and the serine/threonine kinase signaling pathway (18). However, the underlying mechanism of NEK8 regulation requires further investigation (18). In another previous study (19), it was revealed that NEK8 may be a novel target gene for hypoxia-inducible factors (HIFs) and that the von-Hippel-Lindau tumor suppressor protein (pVHL) may downregulate NEK8 expression via HIFs.

It has been well reported that the functions of pVHL, the product of the VHL tumor suppressor gene, may be associated with its role as the substrate-recognition component of an E3 ubiquitin ligase complex, which also contains elongin B, elongin C, cullin 2 and ring-box 1 (20). The aforementioned complex targets HIF-α for ubiquitination and degradation. Although less thoroughly characterized, pVHL also exhibits HIF-independent functions, including regulation of microtubule dynamics, extracellular matrix deposition, responses to DNA damage and primary cilia maintenance (20).

In the present study, it was demonstrated that pVHL may interact with NEK8 and act as an E3 ubiquitin ligase that promotes NEK8 degradation. The results of the present study may improve current knowledge of NEK8 function and regulation.

Materials and methods

Cell culture and reagents. SGC-7901 and SNU-1 cells were obtained from the Type Culture Collection of the Chinese Academy of Science (CASTCC; Shanghai, China) and cultured in an appropriate medium, RPMI-1640 plus 10% fetal bovine serum (FBS), as suggested by CASTCC. Cells were incubated at 37˚C with 5% CO₂. Cycloheximide (CHX) and MG-132 were obtained from MedChemExpress (Shanghai, China).

Plasmid transfection. The plasmids (2 µg) pcDNA3.0-VHL, enhanced green fluorescent protein (EGFP)-NEK8 and influenza hemagglutinin-tagged ubiquitin (HA-Ub) were transfected using Lipofectamine 2000® (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. At 48 h post-transfection, the cells were treated or harvested and subjected to further analyses.

NEK8-knockdown. Stable knockdown of NEK8 in SGC-7901 cells was conducted with the pSUPER RNAi system using Lipofectamine 2000® (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocols. To establish pSUPER-NEK8, the sequences selected from human NEK8 cDNA, 5'-TCGCTCAAGATCGGTATTT-3' and 5'-CTGGAA GCAAGGCCCTTA-3', were synthesized by Sangon Biotech Co., Ltd (Shanghai, China). NEK8-shRNA sequence was inserted in pSUPER vector and empty pSUPER vector was used as the negative control.

Ubiquitination assays. SGC-7901 cells were co-transfected with EGFP-NEK8, HA-Ub and VHL or vector plasmids, respectively. Cells were treated with 10 µM MG-132 for 4 h prior to harvesting. GFP-NEK8 protein was immunoprecipitated from cell lysates using anti-GFP antibody (2 µg; cat. no. sc-101525), and IgG antibody (2 µg; cat. no. sc-2025; both Santa Cruz Biotechnology Inc., Dallas, TX, USA) was used as the control. Proteins from the precipitates were subjected to western blotting with anti-HA antibody (1:1,000; cat. no. sc-7392; Santa Cruz Biotechnology Inc.).

NEK8 half-life assays. The SGC-7901 cells at 48 h after transfection with pcDNA3.0-VHL were exposed to 100 µg/ml cycloheximide for 10, 30 and 60 min to block protein synthesis. The cells were collected for immunoblotting analyses. Changes in relative protein expression levels over time were determined by measuring the optical density of the NEK8 protein bands.

Immunoblotting and immunoprecipitation. Immunoblotting and immunoprecipitation were conducted as previously described (17), using antibodies against NEK8 (1:500; cat. no. sc-50761), HA (1:1,000; cat. no. sc-7392), GFP (1:1,000; cat. no. sc-101525), GAPDH (1:5,000; cat. no. sc-47724; all Santa Cruz Biotechnology Inc.) and VHL (1:500; cat. no. 68547; Cell Signaling Technology Inc., Danvers, MA, USA). In brief, 50 ng protein samples was extracted using RIPA lysis and lysed in sodium dodecyl sulfate (SDS) buffer, separated by 10% SDS-polyacrylamide gel electrophoresis (PAGE), and transferred to PVDF membranes. The membranes were incubated with primary antibodies at 4°C overnight, followed by peroxidase-labeled secondary antibodies (1:2,000; cat. nos. sc-2005 and sc-2030; Santa Cruz Biotechnology Inc.) at room temperature for 1 h. Immunoblots were developed using the ECL Prime Western Blotting Detection system (GE Healthcare Life Sciences, Little Chalfont, UK). For immunoprecipitation, 1 µg primary antibody against VHL was added to 200 µl lysates of 2x10⁶ cells and incubated with rotation at 4°C for 2 h. Rabbit immunoglobulin G (IgG) was used as a negative control. Subsequent to precipitation with agarose A/G (Santa Cruz Biotechnology Inc.), proteins were washed in 100 µl SDS loading buffer (Beyotime Institute of Biotechnology, Haimen, China); 20 µl of each sample was separated by 12% SDS-PAGE and analyzed by immunoblotting using an antibody against NEK8.

Kaplan-Meier survival analysis. The Kaplan-Meier plotter is capable of assessing the effect of 54,675 genes on survival using 10,461 cancer samples, including 5,143 patients with breast cancer, 1,816 with ovarian cancer, 2,437 with lung cancer and 1,065 with GC, with a mean follow-up of 69, 40, 49 and 33 months, respectively. The primary purpose of the tool was a meta-analysis-based biomarker assessment.

Gene expression data and relapse-free and overall survival information were downloaded from GEO (https://www.ncbi.nlm.nih.gov/geo); Affymetrix microarrays only; Affymetrix; Thermo Fisher Scientific Inc.), EGA (https://www.ebi.ac.uk/ega/home) and TCGA (https://cancergenome.nih.gov). The database was handled by a PostgreSQL server (https://www.postgresql.org), which integrates gene expression and clinical data simultaneously. To analyze the prognostic value of a
particular gene, the patient samples were split into two groups, according to varying quantile expression of the proposed biomarker. A Kaplan-Meier survival plot was used to compare the two patient cohorts, and the hazard ratio with 95% confidence intervals, and the log-rank P-values were calculated. Each database is updated biannually. For NEK8, the Affy IDs were 1557172_x_at and 1557170_at. All probe sets per gene were selected in the probe set option.

**MTT assay.** Cells (5x10^4 cells/well) were seeded in 96-well plates in complete culture medium. After 24, 48, 72 and 96 h, the reaction was terminated by adding MTT to each well with a final concentration of 0.5 mg/ml. The reaction was allowed to proceed for 3-4 h at 37°C. The formazan crystals were then dissolved by adding 0.1 ml dimethyl sulfoxide. The intensity of the color developed, which is a reflection of the number of live cells, was measured at 490 nm using a multiwell spectrophotometer. All assays were performed with 3 replicates.

**Transwell assay.** SGC-7901 cell migration was evaluated using an 8-mm pore size Transwell system (Corning Star; Corning Life Sciences, Cambridge, MA, USA). Briefly, short hairpin RNA (shRNA)-transfected cells were resuspended in serum-free RPMI-1640 medium at a density of 2x10^5 cells/ml. The upper chamber of the Transwell was loaded with 100 µl cell suspension and the lower chamber was loaded with 0.6 ml RPMI-1640 containing 10% fetal bovine serum. Following 8 h of incubation, the cells that had migrated to the lower chamber were fixed with 100% methanol at 4°C for 15 min and stained with 0.1% crystal violet at room temperature for 15 min. The cell images were captured under a stereomicroscope (Olympus Corporation, Tokyo, Japan), then the cells were washed with 10% acetic acid for the measurement of the optical density at a wavelength of 595 nm.

**Colony formation assay.** A total of 1,000 cells transfected with negative control plasmid associated with the NEK8-shRNA-transfected SGC-7901 cells were mixed with RPMI-1640 containing 0.3% agar and 10% FBS, and plated on 0.6% basal agar in triplicate 6-well plates. The upper well was then further covered with RPMI-1640 containing 10% FBS and incubated at 37°C with 5% CO_2 for 2 weeks, prior to the colony numbers being counted by eye.

**Antitumor activity assay in vivo.** BALB/C-nu/nu mice aged 4-5 weeks were obtained from Zhejiang Academy of Medical Sciences (Hangzhou, China). A total of 24 male mice (mean weight, ~20 g) were housed in sterile cages under laminar airflow hoods at 20°C in a specific pathogen‑free environment. Animals were fed with autoclaved chow and water ad libitum. To further confirm whether pVHL promotes NEK8 degradation via the ubiquitin–proteasome signaling pathway, an ubiquitination experiment was performed. SGC-7901 cells were co-transfected with GFP-NEK8, HA-Ub and pVHL plasmids. Immunoprecipitation was performed with anti-GFP or IgG antibodies, and the ubiquitination of NEK8 protein was determined in the presence or absence of pVHL overexpression. SGC-7901 cells were transfected with pVHL and NEK8 expression levels were subsequently evaluated by immunoblot analysis at various time points following the inhibition of de novo protein synthesis by CHX. The half-life of NEK8 was reduced from >30 to <15 min when pVHL was ectopically expressed (Fig. 1C). The findings of the present study demonstrated that pVHL may promote the rapid degradation of NEK8.

**Results**

**pVHL interacts with NEK8 in SGC-7901 cells.** In a previous study, it was demonstrated that pVHL may regulate NEK8 indirectly via the HIF-1 signaling pathway (17). To verify whether pVHL interacts with NEK8 in cells, immunoprecipitation was performed. As indicated in Fig. 1A, the pull-down effect of the anti-VHL antibody on NEK8 protein was marked, indicating an association between the two proteins. Further investigation was required to examine whether pVHL interacts with NEK8 directly.

**pVHL promotes NEK8 protein degradation via the proteasome-ubiquitin signaling pathway.** The present study proposed that pVHL, an E3 ligase, may promote the degradation of NEK8 protein. Firstly, cells were treated with the 26S proteasome inhibitor, MG-132 (10 µM). This proteasome inhibitor rescued the reduction in NEK8 expression levels induced by pVHL overexpression, indicating that pVHL may mediate the decrease in NEK8 protein by proteasome-executed degradation (Fig. 1B). Subsequently, the half-life of NEK8 protein was determined in the presence or absence of pVHL overexpression. SGC-7901 cells were transfected with pVHL and NEK8 expression levels were subsequently evaluated by immunoblot analysis at various time points following the inhibition of de novo protein synthesis by CHX. The half-life of NEK8 was reduced from >30 to <15 min when pVHL was ectopically expressed (Fig. 1C). The findings of the present study demonstrated that pVHL may promote the rapid degradation of NEK8.

**NEK8 promotes cancer progression.** The Kaplan-Meier estimate was used to assess the effects of 54,675 genes on survival using 1,065 cancer samples from patients with GC, with a mean follow-up of 33 months (http://kmplot.com/analysis/). The primary purpose of the tool is meta-analysis-based biomarker assessment. Online analysis using Kaplan-Meier survival plots based on the transcriptomic data of 1,065 patients...
demonstrated that higher expression levels of NEK8 may lead to poor survival in patients with GC (Fig. 2). All analyses were conducted using standard procedures (19).

To confirm whether NEK8 may promote the progression of cancer, NEK8 expression was downregulated by shRNA. As demonstrated by western blotting (Fig. 3A), NEK8 was efficiently
knocked down in SGC-7901 and SNU-1 cells. In addition, NEK8 downregulation inhibited the proliferation, colony formation ability and migration of SGC-7901 and SNU-1 cells (Fig. 3B-D).

Based on the aforementioned in vitro findings, the present study investigated whether NEK8 may serve a role in gastric cancer cell proliferation in vivo. SGC-7901 and SNU-1 cells transfected with control or NEK8-shRNAs were implanted subcutaneously into the flanks of female nude mice, respectively. As presented in Fig. 4, implanted control cells formed significantly larger tumors compared with NEK8-shRNAs-transfected cells. Additional research is required to investigate the potential underlying mechanisms.

**Discussion**

In the present study, it was demonstrated that pVHL may interact with NEK8 in vitro, as determined by immunoprecipitation, and that pVHL may promote NEK8 degradation via the ubiquitin-proteasome signaling pathway. Additionally, NEK8 knockdown mediated by shRNA inhibited the proliferation, colony formation and migration of the GC SGC-7901 cell line in vitro, and proliferation in vivo.

Bowers and Boylan (21) reported that NEK8 may be a novel tumor-associated gene as revealed by its variable expression in healthy human breast tissue and breast tumors. It has been reported that NEK8 may serve a critical role in the development of cancer via the regulation of DNA damage/repair (17). The present study generated Kaplan-Meier survival plots, which revealed that higher expression levels of NEK8 were associated with a poor survival rate. Furthermore, the present study revealed that RNAi-mediated knockdown of NEK8 effectively suppressed GC cell proliferation, soft-agar colony formation and migration in vitro, and xenograft growth in vivo. The aforementioned data indicate a possible role for NEK8 in gastric tumor progression.
Indirect regulation of NEK8 by pVHL via the HIF-1 signaling pathway has been reported (19). The association between pVHL and NEK8 in SGC-7901 cells was investigated in the present study. Numerous HIF-independent roles of pVHL have been observed by biochemical interactions (22). However, the most documented function of pVHL is its role as the substrate-recognition component of an E3 ubiquitin ligase complex (20). This suggests that NEK8 may serve as a novel target of pVHL. The results of the present study revealed the promoting effects of pVHL on NEK8 protein degradation and ubiquitination. In addition, the study suggested that MG-132 rescued the reduction in NEK8 expression levels induced by pVHL overexpression, which supported the aforementioned hypothesis.

In summary, the findings of the present study may provide novel insight into the signaling pathway underlying the regulation of NEK8 in cancer. Additionally, the data of the present study may provide further insight into the role of pVHL in NEK8 regulation, as well as the role of the NEK8 in the progression of GC. This may improve the understanding of tumor progression and contribute to the development of novel therapeutic strategies.

Acknowledgements
The authors would like to thank Mr. Jian-Xing Zhang (Laboratory for Biological Medicine, School of Medicine, Taizhou University) for providing technical assistance in the animal procedures.

Funding
The present study was supported by the Zhejiang Provincial Natural Science Foundation (grant nos. LY16H310006, LY15H310002 and LY15H310001), The National Natural Science Foundation of China (grant no. 81201530), the Public Technology Research Projects of the Science Technology Department of Zhejiang Province (grant nos. 2016C37111, 2015C37093, 2016C33235 and 2018C37109) and the Science Technology Department of Taizhou City (grant no. 15yw08).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
XFD, GC and YLW designed the study; XFD, JC, JZ and GC performed the research; XFD, GC and YLW analyzed the data; and GC and YLW wrote the manuscript.

Ethics approval and consent to participate
The present study was ethically approved by the Medical Ethics Committee of Taizhou College of Medicine (approval no. TZXYX2017-003).

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1.  Kim HJ and Oh SC: Novel systemic therapies for advanced gastric cancer. J Gastric Cancer 18: 1-19, 2018.
2.  Lauren P: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An Attempt At A Histo-Clinical Classification. Acta Pathol Microbio Scand 64: 31-49, 1965.
3.  Hamilton SR and Aaltonen LA (eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. IARC Press, Lyon, France, 2000.
4.  Cisło M, Filip AA, Arnold Offerhaus GJ, Cisêł B, Rawicz-Pruszyński K, Skierucha M and Polkowski WP: Distinct molecular subtypes of gastric cancer: From Laurén to molecular pathology. Oncotarget 9: 19427-19442, 2018.
5.  Ren D, Lin B, Zhang X, Peng Y, Ye Z, Ma Y, Liang Y, Cao L, Li X, Li R, et al: Maintenance of cancer stemness by miR-196b-5p contributes to chemoresistance of colorectal cancer cells via activating STAT3 signaling pathway. Oncotarget 8: 49807-49823, 2017.
6.  Fry AM, O’Regan L, Sabir SR and Bayliss R: Cell cycle regulation by the NEK family of protein kinases. J Cell Sci 125: 4423-4433, 2012.
7.  Moniz L, Dutt P, Haider N and Stambolic V: Nek family of kinases in cell cycle, checkpoint control and cancer. Cell Div 6: 18, 2011.
8.  Prosser SL, O’Regan L and Fry AM: Novel insights into the mechanisms of mitotic spindle assembly by NEK kinases. Mol Cell Oncol 3: e1062952, 2015.
9.  Jackson PK: Nek8 couples renal ciliopathies to DNA damage and checkpoint control. Mol Cell 51: 407-408, 2013.
10. Otto EA, Trapp ML, Schultheiss UT, Helou J, Quarmby LM and Hildebrandt F: NEK8 mutations affect ciliary and centrosomal localization and may cause nephronophthisis. J Am Soc Nephrol 19: 587-592, 2008.
11. Sohara E, Luo Y, Zhang J, Manning DK, Beier DR and Zhou J: Nek8 regulates the expression and localization of polycystin-1 and polycystin-2. J Am Soc Nephrol 19: 469-476, 2008.

12. Choi HJ, Lin JR, Vannier JB, Staal GG, Kile AC, Paulsen RD, Manning DK, Beier DR, Giles RH, Boulton SJ and Cimprich KA: Nek8 links the ATR-regulated replication stress response and S phase CDK activity to renal ciliopathies. Mol Cell 51: 423-439, 2013.

13. Holland PM, Milne A, Garka K, Johnson RS, Willis C, Sims JE, Rauch CT, Bird TA and Virca GD: Purification, cloning, and characterization of Nek8, a novel NIMA-related kinase, and its candidate substrate Bicd2. J Biol Chem 277: 16229-16240, 2002.

14. Grampa V, Delous M, Zaidan M, Odye G, Thomas S, Elkhartoufi N, Filhol E, Niel O, Silbermann F, Lebreton C, et al: Novel NEK8 mutations cause severe syndromic renal cystic dysplasia through YAP dysregulation. PLoS Genet 12: e1005894, 2016.

15. Vakova N, Yunis R, Mak SK, Kang K and Kültz D: Nek8 mutation causes overexpression of galecin-1, sorcin, and vimentin and accumulation of the major urinary protein in renal cysts of jck mice. Mol Cell Proteomics 4: 1099-1018, 2005.

16. Frank V, Habbig S, Bartram MP, Eisenberger T, Veenstra-Knol HE, Decker C, Boorsma RA, Göbel H, Nürnberg G, Griessmann A, et al: Mutations in NEK8 link multiple organ dysplasia with altered Hippo signalling and increased c-MYC expression. Hum Mol Genet 22: 2177-2185, 2013.

17. Abeyta A, Castella M, Jacquemont C and Taniguchi T: NEK8 regulates DNA damage-induced RAD51 foci formation and replication fork protection. Cell Cycle 16: 335-347, 2017.

18. Czarnecki PG, Gabriel GC, Manning DK, Sergeev M, Lemke K, Klena NT, Liu X, Chen Y, Li Y, San Agustin JT, et al: ANKS6 is the critical activator of NEK8 kinase in embryonic situs determination and organ patterning. Nat Commun 6: 6023, 2015.

19. Ding XF, Zhou J, Hu QY, Liu SC and Chen G: The tumor suppressor pVHL down-regulates never-in-mitosis A-related kinase 8 via hypoxia-inducible factors to maintain cilia in human renal cancer cells. J Biol Chem 290: 1389-1394, 2015.

20. Gossage L, Eisen T and Maher ER: VHL, the story of a tumour suppressor gene. Nat Rev Cancer 15: 55-64, 2015.

21. Bowers AJ and Boylan JD: Nek8, a NIMA family kinase member, is overexpressed in primary human breast tumors. Gene 328: 135-142, 2004.

22. Li M and Kim WY: Two sides to every story: The HIF-dependent and HIF-independent functions of pVHL. J Cell Mol Med 15: 187-195, 2011.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.